{"id":"nectin4","name":"Nectin-4","symbol":"NECTIN4","route":"/targets/nectin4/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19688","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143217","uniprot":"https://www.uniprot.org/uniprotkb/Q96NY8/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q96NY8","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3712928","open-targets":"https://platform.opentargets.org/target/ENSG00000143217","civic":"https://civicdb.org/genes/81607/summary","oncokb":"https://www.oncokb.org/gene/NECTIN4","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NECTIN4","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=NECTIN4","depmap":"https://depmap.org/portal/gene/NECTIN4?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000143217-NECTIN4","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/81607","omim":"https://www.omim.org/entry/609607"}],"products":[{"id":"ak146d1","name":"AK146D1","status":"phase-1","modality":"Bispecific ADC","route":"/drugs/ak146d1/"},{"id":"crb-701","name":"CRB-701","status":"phase-2","modality":"ADC","route":"/drugs/crb-701/"},{"id":"enfortumab-vedotin","name":"Enfortumab vedotin","status":"approved","modality":"ADC","route":"/drugs/enfortumab-vedotin/"},{"id":"zelenectide-pevedotin","name":"Zelenectide pevedotin","status":"phase-2","modality":"Bicycle toxin conjugate (Nectin-4, MMAE)","route":"/drugs/zelenectide-pevedotin/"}],"trials":[{"id":"ev-303","name":"EV-303 / KEYNOTE-905","nct":"NCT03924895","phase":"3","status":"positive"},{"id":"ev-304","name":"EV-304 / KEYNOTE-B15","nct":"NCT04700124","phase":"3","status":"positive"},{"id":"ev-302","name":"EV-302 / KEYNOTE-A39","nct":"NCT04223856","phase":"3","status":"positive"},{"id":"nct07720284","name":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","nct":"NCT07720284","phase":"3","status":"recruiting"},{"id":"nct07566156","name":"Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)","nct":"NCT07566156","phase":"3","status":"recruiting"},{"id":"nct04960709","name":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","nct":"NCT04960709","phase":"3","status":"active"},{"id":"nct07815665","name":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","nct":"NCT07815665","phase":"2/3","status":"recruiting"},{"id":"nct06493552","name":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","nct":"NCT06493552","phase":"2/3","status":"recruiting"},{"id":"nct04225117","name":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","nct":"NCT04225117","phase":"2","status":"active"},{"id":"nct07591090","name":"A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer","nct":"NCT07591090","phase":"2","status":"recruiting"},{"id":"nct07669779","name":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer","nct":"NCT07669779","phase":"2","status":"recruiting"},{"id":"nct07475806","name":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder","nct":"NCT07475806","phase":"2","status":"recruiting"},{"id":"nct06553885","name":"Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC","nct":"NCT06553885","phase":"2","status":"recruiting"},{"id":"nct07825753","name":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","nct":"NCT07825753","phase":"2","status":"planned"},{"id":"nct06225596","name":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","nct":"NCT06225596","phase":"2","status":"active"},{"id":"nct06840483","name":"Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer","nct":"NCT06840483","phase":"2","status":"active"},{"id":"nct06933329","name":"Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer","nct":"NCT06933329","phase":"2","status":"active"},{"id":"nct06305767","name":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","nct":"NCT06305767","phase":"1/2","status":"active"},{"id":"nct06265727","name":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors","nct":"NCT06265727","phase":"1/2","status":"recruiting"},{"id":"nct07287995","name":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","nct":"NCT07287995","phase":"1/2","status":"recruiting"},{"id":"nct06483334","name":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)","nct":"NCT06483334","phase":"1/2","status":"active"},{"id":"nct07299747","name":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","nct":"NCT07299747","phase":"1/2","status":"recruiting"},{"id":"nct04561362","name":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","nct":"NCT04561362","phase":"1/2","status":"active"},{"id":"nct07421700","name":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","nct":"NCT07421700","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["akeso","aktis-oncology","astellas","avenzo","bicycle-therapeutics","corbus-pharmaceuticals","emergence-therapeutics","marengo-therapeutics","pfizer"],"keyPapers":["paper-ev-302-nejm-2024"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}